Who regains the most weight after stopping GLP-1 drugs?
The people who regain the most weight are those who lost the most in the first place, especially on the most potent drugs. In the STEP 1 trial extension [2], participants who had lost an average of 17.3% of their body weight on semaglutide regained 11.6 percentage points (about two-thirds of the loss) within one year of stopping. That means someone who lost 30 kg would regain roughly 20 kg. A meta-analysis of 36 studies [3] confirmed that semaglutide leads to the largest absolute weight regain after stopping—an average of 5.15 kg—compared to 3.06 kg for exenatide, 1.50 kg for liraglutide, and 1.66 kg for orlistat. So the bigger the initial loss, the bigger the potential rebound, but the net loss after one year off drug still averaged 5.6% for semaglutide users [2].
This pattern means that people who achieve dramatic weight loss on GLP-1 drugs are the most vulnerable to rebound, but they also have the most to gain from restarting treatment or using a maintenance strategy. The meta-analysis [3] emphasizes that weight regain is 'common and drug-dependent,' and the STEP 1 data [2] show that cardiometabolic improvements (like blood pressure and cholesterol) also revert toward baseline, so the rebound isn't just cosmetic—it affects health.
Can anyone actually benefit from the weight rebound?
Yes, but the benefit is indirect: the rebound creates a clear need and opportunity for ongoing or resumed treatment, and it can be a therapeutic target in specific situations. For example, a 2026 study [1] found that women who abruptly stopped GLP-1 drugs within 90 days of conception had a 53% higher risk of gestational diabetes, driven by a steeper weight rebound (excess gain of 1.3 kg/m²). This means that for women planning pregnancy, the rebound itself is a danger—but if they plan a gradual discontinuation 6–18 months before pregnancy, the risk drops to normal levels. So the rebound 'benefits' them by forcing careful medical planning that ultimately protects both mother and baby.
Another group that benefits from rebound is people who have had bariatric surgery and then regain weight. A 2025 study [4] of 100 post-surgery patients found that starting GLP-1 drugs (semaglutide or dulaglutide) after weight regain led to a median 25.5% total weight loss at one year, along with major improvements in conditions like sleep apnea (−30%) and hypertension (−40%). For these patients, the rebound after surgery becomes a second chance to lose weight effectively with medication.
Finally, a 2026 study [5] suggests that switching from injectable GLP-1s to a daily oral pill (orforglipron) after stopping injections can help people maintain 75–79% of their earlier weight loss—meaning the rebound is much smaller. So the rebound benefits people by motivating them to find a sustainable long-term strategy, whether that's a different drug, a lower dose, or lifestyle changes.
Who is most harmed by the rebound?
The people most harmed are those who stop GLP-1 drugs abruptly without a plan, especially if they have metabolic vulnerabilities. The pregnancy study [1] is the clearest example: abrupt discontinuation close to conception raised gestational diabetes risk by 53%, and the weight rebound was steeper (excess gain of 1.3 kg/m² vs. 0.6 kg/m² with gradual stopping). This harm is avoidable with proper timing.
More broadly, the STEP 1 trial [2] showed that cardiometabolic improvements (like blood pressure, cholesterol, and blood sugar) all reverted toward baseline within a year of stopping semaglutide. So anyone who stops treatment without a maintenance plan loses not just weight but also the health gains they worked for. The meta-analysis [3] reinforces that this is a universal pattern across GLP-1 drugs, not a rare side effect.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2026, 4 from 2024 or later, 4 in Q1 journals, collectively cited 770 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 58 papers retrieved from a database of over 500 million.
Sources used in this answer
Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
In a retrospective cohort study of 892 matched women, abrupt discontinuation of GLP-1 drugs within 90 days of conception raised gestational diabetes risk by 53% (RR 1.536), while gradual discontinuation 6–18 months before pregnancy showed no increased risk despite a modest BMI rebound.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension
In the STEP 1 trial extension (327 participants), one year after stopping semaglutide, participants regained 11.6 percentage points of lost weight (two-thirds of the 17.3% loss), and cardiometabolic improvements reverted toward baseline, confirming obesity as a chronic condition needing ongoing treatment.
Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs
This meta-analysis of 36 studies found that semaglutide caused the largest weight regain after discontinuation (mean 5.15 kg), followed by exenatide (3.06 kg), orlistat (1.66 kg), and liraglutide (1.50 kg), with moderate to high heterogeneity across studies.
Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery
In 100 post-bariatric surgery patients with insufficient weight loss or weight regain, starting GLP-1 drugs led to a median 25.5% total weight loss at one year, with significant improvements in sleep apnea (−30%), hypertension (−40%), and arthralgia (−56.5%).
GLP-1: Daily pill reduces weight rebound after stopping injections, study suggests.
A small study (376 participants) found that switching to a daily oral GLP-1 pill (orforglipron) after stopping injectable GLP-1s helped people maintain 75–79% of their earlier weight loss, suggesting a strategy to reduce rebound.